Status:
COMPLETED
Unmodified Versus Leuko-Reduced Allogeneic Red Blood Cells Transfusion in Cancer Patients
Lead Sponsor:
Gustave Roussy, Cancer Campus, Grand Paris
Conditions:
Cancer
Surgery
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
There is evidence to suggest that red blood cell concentrate (RBC) transfusion may have immunomodulatory effects. The aim of this randomized single-center trial is to compare immune responses in patie...
Detailed Description
This single-center study is conducted to compare the effect of peroperative transfusion of allogeneic unmodified RBC (UN-RBC) versus leuko-reduced RBC (RED-RBC) on recipient immunity. Patients undergo...
Eligibility Criteria
Inclusion
- Surgery for cancer with a transfusion during surgery risk greater than 30%
- Surgery in curative intent
- Written informed consent
Exclusion
- contraindications to the use of allogeneic unmodified red blood cell concentrate
- any anti-RBC and/or anti-HLA and/or anti-granulocyte alloimmunization
Key Trial Info
Start Date :
September 1 1997
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00180869
Start Date
September 1 1997
Last Update
September 16 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Gustave Roussy
Villejuif, France, 94800